XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Revenues $ 53,473 $ 54,287 $ 157,283 $ 163,489
Gross profit (loss) 33,402 32,765 96,694 100,492
Operating expense 33,469 29,363 97,485 97,689
Operating (loss) income (67) 3,402 (791) 2,803
Nonoperating (income) expense, net 2,013 (1,486) 475 (2,915)
Operating Segments [Member]        
Gross profit (loss) 33,453 32,758 96,755 100,520
Operating expense 33,469 29,363 97,485 97,689
Operating (loss) income (67) 3,402 (791) 2,803
Nonoperating (income) expense, net (2,013) 1,486 (475) 2,915
Earnings (loss) before income taxes 1,946 1,916 (316) (112)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]        
Revenues [1] 19,338 [2] 16,283 52,345 [2] 48,021
Gross profit (loss) 13,951 11,614 38,018 34,581
Operating Segments [Member] | Clinical Genomics [Member]        
Revenues [1] 12,546 15,585 41,464 48,525
Gross profit (loss) 6,449 8,045 20,904 26,535
Operating Segments [Member] | Biopharmaceutical Development [Member]        
Revenues [1] 9,430 11,646 28,526 34,757
Gross profit (loss) 5,841 7,359 17,783 21,993
Operating Segments [Member] | Calibration Solutions [Member]        
Revenues [1] 12,159 10,773 34,948 32,186
Gross profit (loss) 7,212 5,740 20,050 17,411
Corporate, Non-Segment [Member]        
Revenues [1],[3] $ (51) $ 7 $ (61) $ (28)
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues from GKE GmbH and SAL GmbH are included in the Sterilization and Disinfection Control division beginning upon acquisition on October 16, 2023.
[3] Unallocated corporate expenses and other business activities are reported within Corporate and Other.